Although the introduction of PD-1 or PD-L1 inhibitors into clinical practice has revolutionized cancer treatment, consistent response and beneficial long-term results have only been observed in few patients.[4] Furthermore, several treatment-related side effects have been noted following first-line therapy with PD-L1 inhibitors in combination with chemotherapy[5] or PD-L1 inhibitors alone.[6]. The gene discussed is CD274; the disease is cancer.